Opinion Article Open Access

Rewiring the Immune Battlefield: The Transformative Promise of Immunotherapy in Lung Cancer

Abstract

Lung cancer remains one of the most lethal malignancies worldwide, largely due to late-stage diagnosis and limited efficacy of traditional therapies such as chemotherapy and radiation. Over the past decade, immunotherapy has emerged as a paradigm-shifting approach, harnessing the body’s immune system to recognize and eliminate tumor cells. This article explores the evolution, mechanisms, clinical outcomes, and challenges of lung cancer immunotherapy, with a focus on immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines. While immunotherapy has significantly improved survival rates in subsets of patients, variability in response, immune-related adverse effects, and high costs remain barriers to universal success. Future directions emphasize biomarker-driven personalization, combination strategies, and novel immune targets. The article argues that although immunotherapy is not a universal cure, it represents one of the most promising advances in modern oncology.

Eleanor Whitcombe

To read the full article Download Full Article